SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,725 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,725 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.63, for a total value of $69,396.75. Following the completion of the transaction, the senior vice president directly owned 273,650 shares in the company, valued at approximately $5,098,099.50. This represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Up 2.4%

SIBN stock opened at $19.14 on Wednesday. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The stock has a market capitalization of $848.86 million, a price-to-earnings ratio of -56.29 and a beta of 0.66. The business’s fifty day moving average price is $17.22 and its two-hundred day moving average price is $15.25.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $56.01 million during the quarter, compared to analysts’ expectations of $55.34 million. On average, equities analysts anticipate that SiBone will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On SiBone

A number of large investors have recently bought and sold shares of SIBN. Hussman Strategic Advisors Inc. bought a new stake in SiBone in the fourth quarter worth about $1,656,000. UBS Group AG increased its stake in shares of SiBone by 570.2% during the 4th quarter. UBS Group AG now owns 104,731 shares of the company’s stock worth $2,065,000 after purchasing an additional 89,105 shares during the last quarter. Impax Asset Management Group plc raised its holdings in shares of SiBone by 17.1% in the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock worth $23,664,000 after purchasing an additional 175,000 shares during the period. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of SiBone in the 4th quarter worth approximately $838,000. Finally, HighMark Wealth Management LLC lifted its stake in SiBone by 549.7% in the fourth quarter. HighMark Wealth Management LLC now owns 159,832 shares of the company’s stock valued at $3,152,000 after purchasing an additional 135,232 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on SIBN shares. TD Cowen increased their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Truist Financial reiterated a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. UBS Group boosted their price target on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings downgraded SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, SiBone presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.